| ID | 1156 |
| Name of the vaccine | HibTITER |
| Microbe | Bacteria |
| Disease name | Haemophilus influenzae type b (Hib) |
| Name of bacteria | Haemophilus influenzae |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | 2 months to 5 years |
| Description of the vaccine | Haemophilus b conjugate vaccine (tetanus toxoid conjugate) (HbOC). |
| Name of the manufacturer | Lederle-Praxis |
| Name of the manufacturing country | NA |
| Year of manufacture | 1989 |
| Clinical Phase status | Approved |
| Bacterial strain | Anaerobic gram-negative coccobacillus. |
| Efficacy | Titer of antibody 0.15 µg/mL correlates with protection and greater than 1.0 µg/mL is associated with long-term protection. |
| Vaccine formulation | Powder for Solution, Suspension |
| Dosage | First dose at 2 to 6 months, followed by 2 more doses at least 8 weeks apart. Booster dose at 15 to 18 months. |
| Mechanism of action | IgG anti-HbPs antibodies of IgG1 subclass predominated. |
| Route of administration | Intramuscular |
| Indications | Immunization of children against invasive diseases caused by H. influenzae type b. |
| Export | ACIP |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | More common : Diarrhoea, loss of appetite, vomiting.
Less common : Earache, redness or swelling in the ear. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.drugs.com/cons/hibtiter.html |
| Other name | NA |
| Additional Links | https://www.rxlist.com/hibtiter-drug.htm#clinpharm
|